Evidence map›Paper›PMID 33643816›Full record

ReviewActa pharmaceutica Sinica. B2021

Long non-coding RNAs: From disease code to drug role.

Yuanyuan Chen, Zhaojun Li, Xiaoguang Chen, Sen Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 308 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
308citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

308 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. The Footprint ofCurrent Alzheimer research · 2025
    Pooled it
  3. Pooled it
  4. lncRNAInternational journal of molecular medicine · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Steroid hormone ouabain cooperates with NaActa pharmaceutica Sinica. B · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

248 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuanyuan ChenState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
Zhaojun LiState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
Xiaoguang ChenState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
Sen ZhangState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enormous studies have corroborated that long non-coding RNAs (lncRNAs) extensively participate in crucial physiological processes such as metabolism and immunity, and are closely related to the occurrence and development of tumors, cardiovascular diseases, nervous system disorders, nephropathy, and other diseases. The application of lncRNAs as biomarkers or intervention targets can provide new insights into the diagnosis and treatment of diseases. This paper has focused on the emerging research into lncRNAs as pharmacological targets and has reviewed the transition of lncRNAs from the role of disease coding to acting as drug candidates, including the current status and progress in preclinical research. Cutting-edge strategies for lncRNA modulation have been summarized, including the sources of lncRNA-related drugs, such as genetic technology and small-molecule compounds, and related delivery methods. The current progress of clinical trials of lncRNA-targeting drugs is also discussed. This information will form a latest updated reference for research and development of lncRNA-based drugs.

Indexed as

AD, Alzheimer's diseaseANRIL, antisense noncoding RNA gene at the INK4 locusASncmtRNAASncmtRNA, antisense noncoding mitochondrial RNAASO, antisense oligonucleotideBCAR4, breast cancer anti-estrogen resistance 4BDNF-AS, brain-derived neurotrophic factor antisenseCASC9, cancer susceptibility candidate 9CDK, cyclin dependent kinase 1CHRF, cardiac hypertrophy related factorClinical trialsCRISPR, clustered regularly interspaced short palindromic repeatsDACH1, dachshund homolog 1DANCR, differentiation antagonizing non-protein coding RNADeliveryDKD, diabetic kidney diseaseDPF, diphenyl furanEBF3-AS, early B cell factor 3-antisenseENE, element for nuclear expressionErbb4-IR, Erb-B2 receptor tyrosine kinase 4-immunoreactivityFDA, U.S. Food and Drug AdministrationGAPDH, glyceraldehyde-3-phosphate dehydrogenaseGAS5, growth arrest specific 5Gene therapyHISLA, HIF-1α-stabilizing long noncoding RNAHOTAIR, HOX transcript antisense intergenic RNAHULC, highly upregulated in liver cancerlincRNA-p21, long intergenic noncoding RNA p21LIPCAR, long intergenic noncoding RNA predicting cardiac remodelingLNAs, locked nucleic acidsLncRNAslncRNAs, long non-coding RNAsMALAT1, metastasis associated lung adenocarcinoma transcript 1MEG3, maternally expressed gene 3MHRT, myosin heavy chain associated RNA transcriptsMM, multiple myelomamtlncRNA, mitochondrial long noncoding RNANEAT1, nuclear enriched abundant transcript 1NKILA, NF-kappaB interacting lncRNANorad, non-coding RNA activated by DNA damageNPs, nanoparticlesOIP5-AS1, opa-interacting protein 5 antisense transcript 1PD, Parkinson's diseasePEG, polyethylene glycolpHLIP, pH-low insertion peptidePNAs, peptide nucleic acidsPTO, phosphorothioatePVT1, plasmacytoma variant translocation 1RGD, arginine-glycine-aspartic acid peptideRISC, RNA-induced silencing complexSALRNA1, senescence associated long non-coding RNA 1sgRNA, single guide RNAsiRNAs, small interfering RNAsSmall moleculesSncmtRNA, sense noncoding mitochondrial RNASNHG1, small nucleolar RNA host gene 1Targeted drugTHRIL, TNF and HNRNPL related immunoregulatoryTncRNA, trophoblast-derived noncoding RNATranslational medicineTTTY15, testis-specific transcript, Y-linked 15TUG1, taurine-upregulated gene 1TWIST1, twist family BHLH transcription factor 1UCA1, urothelial carcinoma-associated 1UTF1, undifferentiated transcription factor 1XIST, X-inactive specific transcript

Identifiers

PMID33643816
PMCPMC7893121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.